This article comes close:
A group of researchers from Boston University, the NIH and the Norwegian Radium Hospital Research Foundation set out to quantify the contribution of PSRIs toward development of drugs and vaccines that have been approved for use by the U.S. Food and Drug Administration. The task required them to spend a great deal of time with the FDA’s Orange Book, which details the patent history of all new drug applications that were ultimately approved. They also scoured news reports and company announcements and surveyed academic technology licensing officers to catch any other drugs they might have missed.
Altogether, they gave 75 PSRIs credit for inventing 153 new drugs that won FDA approval from 1970 to 2009. The NIH was responsible for 22 of the drugs on that list, and the University of California system came in second with 11. Rounding out the top five PSRIs were Memorial Sloan-Kettering Cancer Center in New York with eight, Emory University in Atlanta with seven, and Yale University in New Haven, Conn., with six. Virtually half of the new drugs were developed for treating cancer or infectious disease.
And these weren’t just run-of-the-mill drugs – they were important ones. For instance, 46% of the drugs developed by PSRIs got priority reviews from the FDA (an indication that they offered a substantial improvement over existing treatments), compared with 20% of the drugs from the private sector.
In addition, the researchers wrote, “Virtually all the important, innovative vaccines that have been introduced during the past 25 years have been created by PSRIs.”